← Oncology Approval Tracker

FDA DECISION ·

Lynparza

olaparib · AstraZeneca

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic castration-resistant prostate cancer and a deleterious or suspected deleterious germline or somatic HRR gene alteration who progressed after enzalutamide or abiraterone.

LAMPGEN ANALYSIS

Why it matters

Extended PARP inhibition to an HRR-defined prostate cancer population after progression on androgen receptor-directed therapy.

What research teams should watch

Check that the alteration is among those covered by the label and capture the prior androgen receptor therapy.

PRIMARY RECORDS

Sources